Restylane Silk Acne Scar Efficacy Evaluation Study

NCT ID: NCT02955381

Last Updated: 2019-05-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-28
• Study Completion Date: 2019-04-18

Brief Summary

Randomized, double-blind, placebo-controlled, research pilot study. 30 subjects aged 22-55 years old of all skin types will be asked to sign an informed consent form prior to any study procedures. Subjects must have at least 1 but up to 3 acne scars ≥3 mm or ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk or Placebo) in each scar at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will be asked to come to 10 visits: Screening visit (up to 35 days prior to Baseline), Baseline (Day 0), Day 7, Day 14, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6 (study exit visit). The treatment area will be evaluated at each visit by the unblinded investigator regarding erythema, bruising, inflammation, itching, stinging/burning, brightness, fullness, smoothness, and clarity. Safety and adverse events will be captured at each visit only by the unblinded investigator.

Detailed Description

Randomized, double-blind, placebo-controlled, research pilot study. 30 subjects aged 22-55 years old of all skin types will be asked to sign an informed consent form prior to any study procedures. Subjects must have at least 1 but up to 3 acne scars ≥3 mm or ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk or Placebo) in each scar at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will be asked to come to 10 visits: Screening visit (up to 35 days prior to Baseline), Baseline (Day 0), Day 7, Day 14, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6 (study exit visit). The blinded investigators will evaluate the target scar using the Acne Scar Rating Scale (ASRS), rate the target acne scar regarding treatment effect on a -5 ("Markedly worse"), to 0 ("Neutral Improvement"), to 5 (Markedly Improved (Clear or nearly clear)) point scale, and evaluate the skin quality (regarding brightness, fullness, smoothness, and clarity). Subjects will give the acne scar a score on the subject VAS acne scar satisfaction scale marking between 0 ("Not satisfied with Acne Scar at Day 0") and 10 ("Extremely Satisfied with Acne Scar at Day 0"). The treatment area will be evaluated at each visit by the unblinded investigator regarding erythema, bruising, inflammation, itching, stinging/burning, brightness, fullness, smoothness, and clarity. The subject will have their vital signs taken, complete a symptom diary (only if the subject experiences side effects or adverse events), complete a DLQI, and have photos (VECTRA and 2D digital photographs) taken of the treatment area. Efficacy measures will only be completed by the blinded investigator. Safety and adverse events will be captured at each visit only by the unblinded investigator.

Conditions

Acne; Acne Scars; AdverseEvent

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Restylane Silk, 1.0 ml

Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.

Group Type: EXPERIMENTAL

Restylane Silk, 1.0 ml

Intervention Type: DEVICE

Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.

Placebo (Saline), 1.0 ml

Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.

Group Type: PLACEBO_COMPARATOR

Saline, 1.0 ml

Intervention Type: DEVICE

Simple saline solution. To be used as placebo (control). No active ingredients.

Interventions

Restylane Silk, 1.0 ml

Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.

Intervention Type: DEVICE

Saline, 1.0 ml

Simple saline solution. To be used as placebo (control). No active ingredients.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Male or non-pregnant female subjects on an acceptable form of birth control aged 22-55 years of age.

2. Willing to refrain from undergoing any procedures to repair or augment any acne scar in the treatment area during the study.

3. Female subjects with a negative pregnancy test confirmed at screening and on an acceptable form of birth control. Acceptable forms of birth control on this study include oral or injectable contraceptive, contraceptive patches, Depo-Provera, NuvaRing, Implanon, double barrier methods, IUD, same sex partner, or abstinence. Males will be required to use an acceptable method of birth control: vasectomy, double-barrier method, condom with spermicidal lube, or abstinence.

4. Signed informed consent prior to conducting any study procedures.

5. Willing to refrain from undergoing any cosmetic procedures in the treatment area during the study.

6. At least one acne scar located on the cheeks or forehead to be ≥ 3 mm and ≤ 10 mm in diameter, and rated as ≥3 on the ASRS at day 0. Subjects may have up to three qualifying acne scars determined eligible for treatment at screening.

7. Acne scars that are classified as either ice pick, rolling, or boxcar acne scars.

8. ≤15 pustules/papules on the face at the time of screening and ≤ 2 nodules, and no cysts at Baseline.

9. Willing to attend all study visits and comply with protocol

Exclusion Criteria

1. Subjects with active cystic acne at screening (> 2 nodules or any cysts present at Baseline).

2. Use of antibiotics 2-weeks prior to screening.

3. Use of retinoids 2-weeks prior to screening.

4. Use of salicylic acid or benzoyl peroxide 7 days prior to screening.

5. Excessive facial hair, skin conditions, facial tattoos, or other dermatologic marks that would obscure the treatment area.

6. Use of Isotretinoin (Accutane) 6 months prior to screening.

7. Semi-permanent or permanent injection in the face 3 months prior to screening.

8. History of bleeding disorders.

9. Use of blood thinners (i.e warfarin (Coumadin), clopidogrel bisulfate (Plavix), etc.) 1 month prior to screening.

10. Acne scars that are considered post-inflammatory erythematous, post-inflammatory hyperpigmentation, varicella (chicken pox) scars, or perifollicular elastolysis will not be allowed to be identified as the target acne scars. These types of scars are still allowed to be present but cannot be selected.

11. Acne scars that are located in the glabella and temple regions. Acne scars located in these regions will not be allowed to be selected as a target or additional acne scar. As well, scars located in these areas will not be allowed to be treated during the study. Subjects are allowed to have acne scars located in these areas but cannot have them selected for evaluation or treated during the study.

12. Laser or light (red and blue) treatments for acne 3 months prior to screening.

13. Resurfacing procedures (CO2 , Erbium, Fraxel, etc.) performed 6 months prior to screening.

14. Any chemical peels in the last 30 days prior to screening.

15. Hypersensitivity to amid-type local anesthetics.

16. Any cortisol steroid or ILK injection 30 days prior to screening

17. Subjects with a history of diabetes.

18. Any medical condition or diagnosis which in the investigator's opinion would disqualify them from the research study.

19. History of abuse with the use of alcohol or drugs.

20. Participation in a clinical trial or use of an investigational product in the past 30 days.

21. Subjects who are considered health risks for participation in the study or the investigator determines not to be suitable.

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Schweiger Dermatology, PLLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric S Schweiger, M.D.

Role: PRINCIPAL_INVESTIGATOR

CEO & Chief Medical Officer

Margaret J Tropeano, BS

Role: STUDY_DIRECTOR

Clinical Research Director

Locations

Schweiger Dermatology, PLLC

New York, New York, United States

Countries

United States

References

Fife D. Practical evaluation and management of atrophic acne scars: tips for the general dermatologist. J Clin Aesthet Dermatol. 2011 Aug;4(8):50-7.

Reference Type: BACKGROUND

PMID: 21909457 (View on PubMed)

Brandt FS, Cazzaniga A. Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging. 2008;3(1):153-9. doi: 10.2147/cia.s2135.

Reference Type: BACKGROUND

PMID: 18488885 (View on PubMed)

Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994 Jul;19(4):303-8. doi: 10.1111/j.1365-2230.1994.tb01200.x.

Reference Type: BACKGROUND

PMID: 7955470 (View on PubMed)

Koo JY, Smith LL. Psychologic aspects of acne. Pediatr Dermatol. 1991 Sep;8(3):185-8. doi: 10.1111/j.1525-1470.1991.tb00856.x.

Reference Type: BACKGROUND

PMID: 1836060 (View on PubMed)

Rivera AE. Acne scarring: a review and current treatment modalities. J Am Acad Dermatol. 2008 Oct;59(4):659-76. doi: 10.1016/j.jaad.2008.05.029. Epub 2008 Jul 26.

Reference Type: BACKGROUND

PMID: 18662839 (View on PubMed)

Tsao SS, Dover JS, Arndt KA, Kaminer MS. Scar management: keloid, hypertrophic, atrophic, and acne scars. Semin Cutan Med Surg. 2002 Mar;21(1):46-75. doi: 10.1016/s1085-5629(02)80719-2. No abstract available.

Reference Type: BACKGROUND

PMID: 11911537 (View on PubMed)

Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol. 2001 Jul;45(1):109-17. doi: 10.1067/mjd.2001.113451.

Reference Type: BACKGROUND

PMID: 11423843 (View on PubMed)

Sadick NS, Palmisano L. Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat. 2009;20(5):302-7. doi: 10.1080/09546630902817879.

Reference Type: BACKGROUND

PMID: 19340629 (View on PubMed)

Lizzul PF, Narurkar VA. The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation. J Drugs Dermatol. 2010 May;9(5):446-50.

Reference Type: BACKGROUND

PMID: 20480786 (View on PubMed)

Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am. 2007 Feb;15(1):63-76, vii. doi: 10.1016/j.fsc.2006.11.002.

Reference Type: BACKGROUND

PMID: 17317557 (View on PubMed)

Fife D, Zachary CB. Combining techniques for treating acne scars. Current Dermatology Reports. 2012;1:82-88.

Reference Type: BACKGROUND

Werschler, Phillip, et al.

Reference Type: BACKGROUND

Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg. 2008 Jun;34 Suppl 1:S92-9. doi: 10.1111/j.1524-4725.2008.34249.x.

Reference Type: BACKGROUND

PMID: 18547189 (View on PubMed)

Hession MT, Graber EM. Atrophic acne scarring: a review of treatment options. J Clin Aesthet Dermatol. 2015 Jan;8(1):50-8.

Reference Type: BACKGROUND

PMID: 25610524 (View on PubMed)

Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg. 1998 Dec;24(12):1317-25. doi: 10.1111/j.1524-4725.1998.tb00007.x.

Reference Type: BACKGROUND

PMID: 9865196 (View on PubMed)

Werschler, P. (2016). Severe - Depth = >2.5 mm in depth. Visibility = Substantial shadowing with tangential lighting. Journal of Drugs in Dermatology, 15(5), 518-525

Reference Type: BACKGROUND

Other Identifiers

SDG 02-2016

Identifier Type: -

Identifier Source: org_study_id